PRESTIGE BIOLOGICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,130 KRW | +0.12% |
|
-0.72% | -6.14% |
| Sales 2022 | 15.57 21.21K 1.3K | Sales 2023 | 1.75K 2.38M 146K | Capitalization | 273B 3,71,420B 22,738B |
|---|---|---|---|---|---|
| Net income 2022 | -49.72B -67,756B -4,148B | Net income 2023 | -39.44B -53,752B -3,291B | EV / Sales 2022 | 19,91,71,88,831 x |
| Net Debt 2022 | 103B 1,40,690B 8,613B | Net Debt 2023 | 115B 1,56,151B 9,559B | EV / Sales 2023 | 22,17,41,268 x |
| P/E ratio 2022 |
-4.55
x | P/E ratio 2023 |
-6.63
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 44.64% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.12% | ||
| 1 week | -0.72% | ||
| Current month | +0.24% | ||
| 1 month | -5.71% | ||
| 3 months | -0.36% | ||
| 6 months | -18.38% | ||
| Current year | -6.14% |
1 week
4 035.00
4 195.00
1 month
4 000.004 690.00
Current year
3 850.005 550.00
1 year
3 850.005 550.00
3 years
2 790.0017 600.00
5 years
2 790.0021 550.00
10 years
2 790.0021 550.00
| Managers | Title | Age | Since |
|---|---|---|---|
Duk-Hoon Hyun
CEO | Chief Executive Officer | - | - |
Yeong-Su Im
DFI | Director of Finance/CFO | 61 | 01/19/01 |
U-Seok Go
BRD | Director/Board Member | 59 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jae-Yeong Yang
BRD | Director/Board Member | 60 | 01/19/01 |
Tae-Won Ban
BRD | Director/Board Member | 50 | 01/19/01 |
U-Seok Go
BRD | Director/Board Member | 59 | 01/20/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 4,130 | +0.12% | 88,722 |
| 02/24/02 | 4,125 | +0.12% | 44,564 |
| 30/24/30 | 4,120 | -0.36% | 70,953 |
| 29/24/29 | 4,135 | -0.60% | 63,613 |
| 26/24/26 | 4,160 | -0.72% | 48,037 |
End-of-day quote Korea S.E., May 03, 2024
More quotes
Prestige Biologics Co Ltd is a Korean-based company mainly engaged in the business of developing and manufacturing biopharmaceuticals. The Company mainly engages in the contract manufacturing service business that produces and supplies biopharmaceuticals; and contract development service business that provides development services including cell culture process and purification process.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.14% | 187M | |
| +1.45% | 40.51B | |
| -15.94% | 31.67B | |
| +52.66% | 24.62B | |
| -14.50% | 15.65B | |
| -14.38% | 12.07B | |
| -9.12% | 11.97B | |
| -42.56% | 11.61B | |
| +4.87% | 8.81B | |
| -4.33% | 8.5B |
- Stock Market
- Equities
- A334970 Stock
